An integrated molecular profile of endometrioid ovarian cancer.
Corrigendum to "Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for reproductive medicine evidence-based review" [Gynecol. Oncol. 155 (2019) 508-514].
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Parti...
An adverse event (AE) is any untoward medical occurrence that occurs in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have to have a causal relationship w...
Ribociclib and Letrozole Treatment in Ovarian Cancer
Determine the response rate of patients receiving the combination of Ribociclib and Letrozole